Talaris Therapeutics Insiders
TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris Therapeutics employs about 84 people. The company is managed by 10 executives with a total tenure of roughly 196 years, averaging almost 19.0 years of service per executive, having 8.4 employees per reported executive. Breaking down Talaris Therapeutics' management performance can provide insight into the firm performance.
Talaris |
Talaris Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2281) % which means that it has lost $0.2281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4164) %, meaning that it created substantial loss on money invested by shareholders. Talaris Therapeutics' management efficiency ratios could be used to measure how well Talaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Talaris Therapeutics Workforce Comparison
Talaris Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,470. Talaris Therapeutics holds roughly 84.0 in number of employees claiming about 6% of equities under Health Care industry.
Talaris Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Talaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Talaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Talaris Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Requadt Scott over a year ago Payment of 11786 shares by Requadt Scott of Talaris Therapeutics subject to Rule 16b-3 | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 16870 shares of Talaris Therapeutics | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 75001 shares of Talaris Therapeutics | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 7841 shares of Talaris Therapeutics | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 15713 shares of Talaris Therapeutics | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 15004 shares of Talaris Therapeutics | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 21753 shares of Talaris Therapeutics | ||
Ildstad Suzanne over a year ago Sale by Ildstad Suzanne of 99771 shares of Talaris Therapeutics |
Talaris Therapeutics Notable Stakeholders
A Talaris Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Talaris Therapeutics often face trade-offs trying to please all of them. Talaris Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Talaris Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nancy MD | Chief Officer | Profile | |
Eric Gornstein | Head Planning | Profile | |
Suzanne Tollerud | VP Devel | Profile | |
Michael Zdanowski | Chief Officer | Profile | |
JD LLB | CEO and President | Profile | |
Suzanne MD | Member Founder | Profile | |
Mary Fenton | CFO Treasurer | Profile | |
Farah Natoli | Head Management | Profile | |
Colby Suire | Head RD | Profile | |
Andrew Farnsworth | Chief Officer | Profile |
About Talaris Therapeutics Management Performance
The success or failure of an entity such as Talaris Therapeutics often depends on how effective the management is. Talaris Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Talaris management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Talaris management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.
Please note, the imprecision that can be found in Talaris Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Talaris Therapeutics. Check Talaris Therapeutics' Beneish M Score to see the likelihood of Talaris Therapeutics' management manipulating its earnings.
Talaris Therapeutics Workforce Analysis
Traditionally, organizations such as Talaris Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Talaris Therapeutics within its industry.Talaris Therapeutics Manpower Efficiency
Return on Talaris Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 879.7K | |
Net Loss Per Executive | 7.4M | |
Working Capital Per Employee | 2.1M | |
Working Capital Per Executive | 17.4M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |